Clinical Trial Update: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update on combining cemiplimab with platinum-based chemotherapy for non-small cell lung cancer. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (Libtayo) (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED